Ractigen Therapeutics

Focus: Ractigen Therapeutics is a China-based biotech company focused on small activating RNA (saRNA) technology for gene therapy applications. The company is in early-stage development with a public listing but remains pre-revenue.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Ractigen Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Ractigen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RAG-17

Gene Mutation

PHASE_1

Clinical Trials (1)

NCT05903690Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

Phase 1

Help build intelligence for Ractigen Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering saRNA platform represents a differentiated modality with potential to address rare genetic diseases including ALS and DMD
Public company status provides liquidity and potential equity upside for early employees in a novel technology space
Access to China's biotech ecosystem and potential government support for rare disease therapeutics

Watch Out For

All 4 programs remain in Phase 1 with no advancement to Phase 2, indicating significant clinical risk and extended timelines to value inflection
Zero active job openings and no disclosed employee count suggest minimal near-term hiring or organizational expansion
Pre-revenue status with unknown funding and financial metrics creates uncertainty around cash runway and sustainability

Generated by Claude from Ractigen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RAG-18

Duchenne Muscular Dystrophy (DMD)

PHASE_1

Clinical Trials (1)

NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy

Phase 1

RAG-17

Amyotrophic Lateral Sclerosis

PHASE_1

Clinical Trials (1)

NCT06556394A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Phase 1

RAG-01

Non-Muscle-Invasive Bladder Cancer (NMIBC)

PHASE_1

Clinical Trials (1)

NCT06351904A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Phase 1